Sign In
Buy ZYXI
$0.125
+0 (+0%)
At Close: Mar 20, 2026
All You Need to Know About Zynex (ZYXI) Rating Upgrade to Buy
01:06pm, Wednesday, 26'th Jun 2024
Zynex (ZYXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally
06:00am, Monday, 24'th Jun 2024
Generally, when the masses – including the market's heavy hitters – decide to bet against a security, it's best to avoid it. However, the unique nuances involved with shorting a company opens the
Analyst Predictions: 3 Stocks Pegged to Soar Over 40% in One Year
06:00am, Wednesday, 19'th Jun 2024
Tracking information on which stocks to buy can be a daunting and time-consuming process. One way to streamline it is to consider analyst EPS, growth and other forecasts, as well as price targets.
Is Zynex (ZYXI) Stock Undervalued Right Now?
10:45am, Wednesday, 12'th Jun 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Zynex to Participate in Fireside Chat with RBC Capital Markets on Thursday, June 13, 2024
09:30am, Monday, 10'th Jun 2024
ENGLEWOOD, Colo. , June 10, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain
Should Value Investors Buy Zynex (ZYXI) Stock?
10:46am, Monday, 27'th May 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Zynex (ZYXI) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Thursday, 23'rd May 2024
Zynex (ZYXI) possesses solid growth attributes, which could help it handily outperform the market.
Are Investors Undervaluing Zynex (ZYXI) Right Now?
10:46am, Thursday, 09'th May 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Zynex to Present at the RBC Capital Markets Global Healthcare Conference
09:15am, Thursday, 09'th May 2024
ENGLEWOOD, Colo. , May 9, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain ma
3 Reasons Growth Investors Will Love Zynex (ZYXI)
01:46pm, Tuesday, 07'th May 2024
Zynex (ZYXI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zynex Executives Recognized Among Top 25 in Medical Technology
09:15am, Tuesday, 07'th May 2024
ENGLEWOOD, Colo. , May 7, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain ma
Zynex, Inc. (ZYXI) Q1 2024 Earnings Call Transcript
09:02pm, Tuesday, 30'th Apr 2024
Zynex, Inc. (NASDAQ:ZYXI ) Q1 2024 Earnings Conference Call April 30, 2024 4:15 PM ET Company Participants Quinn Callanan - CFA, Investor Relations Thomas Sandgaard - Chairman Of The Board, President
Zynex Reports First Quarter 2024 Financial Results
04:01pm, Tuesday, 30'th Apr 2024
Q1 2024 Revenue Increased 10% to $46.5 Million ENGLEWOOD, Colo. , April 30, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture an
Zynex Sets First Quarter 2024 Earnings Call
09:15am, Thursday, 18'th Apr 2024
ENGLEWOOD, Colo. , April 18, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pai
3 Industrial Stocks Short Sellers Are Hammering: Cracks in the Foundation?
02:58pm, Tuesday, 02'nd Apr 2024
There are some industrial stocks that short sellers are targeting heavily in April this year. Short sellers often target stocks they perceive to be overvalued or companies facing significant challenge
